SEC Form 4 · accession 0001209191-17-046194
Intellia Therapeutics, Inc. · NTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank Verwiel
Director
Period of report
Jul 25, 2017
Accepted (ET)
Jul 25, 2017 · 4:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001652130
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $16.91 | Jul 25, 2017 | A | 38,000 | A | — | Jul 24, 2027 | Common Stock | 38,000 | 38,000 | D |
Explanation of responses
- F1This option was granted on July 25, 2017 with respect to 38,000 shares of Common Stock, with 33% vesting on July 25, 2018 and the remaining 67% vesting in eight substantially equal quarterly installments thereafter.